2. Signaling Pathways
  3. Epigenetics
  4. Small Interfering RNA (siRNA)

Small Interfering RNA (siRNA)

Small Interfering RNA (siRNA) is a small exogenous double-stranded RNA (dsRNA) (20-25 nucleotides), which triggers the RNA interference (RNAi) pathway. The short dsRNA unwinds and the sense strand is degraded. Antisense strand forms RNA induced silencing complex (RISC) with various protein components. The antisense strand retained in RISC is specifically complementary to the target gene mRNA. Meanwhile, RISC has nuclease activity, which can cut and degrade the target gene mRNA, and inhibit the expression of target gene. Incomplete complementarity results in mRNA translation inhibition.

Small Interfering RNA (siRNA) Related Products (29532):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-132591A
    Inclisiran sodium
    		98.10%
    Inclisiran sodium is a double-stranded small interfering RNA (siRNA) molecule. Inclisiran sodium inhibits the transcription of PCSK9. Inclisiran sodium inhibits Pyroptosis, activates PPARγ, and reduces NLRP3, cleaved caspase-1, IL-1β, and IL-18. Inclisiran sodium has anti-inflammatory, lipid-regulating and anti-atherosclerotic activities. Inclisiran sodium can be used in researches of hyperlipidemia and cardiovascular disease (CVD).
    Inclisiran sodium
  • HY-150150
    SiRNA Negative Control
    SiRNA Negative Control is a siRNA of 21 nucleotides, and can be used as a negative control. SiRNA Negative Control has no homology to most known gene sequence. SiRNA Negative Control is available with fluorescent labels, allowing rapid assessment of transfection efficiency. SiRNA Negative Control can be used in human, mouse and rat cells in vitro. SiRNA Negative Control can be used as experimental control benchmark, verification of experimental reliability and standardization reference. SiRNA Negative Control is a common negative control used in most research articles.
    SiRNA Negative Control
  • HY-132609
    Patisiran sodium
    		99.09%
    Patisiran sodium is a double-stranded small interfering RNA that targets a sequence within the transthyretin (TTR) messenger RNA. Patisiran sodium specifically inhibits hepatic synthesis of mutant and wild-type TTR. Patisiran sodium can be used for the research of hereditary TTR amyloidosis.
    Patisiran sodium
  • HY-132591
    Inclisiran
    		99.80%
    Inclisiran is a double-stranded small interfering RNA (siRNA) molecule. Inclisiran inhibits the transcription of PCSK9. Inclisiran inhibits Pyroptosis, activates PPARγ, and reduces NLRP3, cleaved caspase-1, IL-1β, and IL-18. Inclisiran has anti-inflammatory, lipid-regulating and anti-atherosclerotic activities. Inclisiran can be used in researches of hyperlipidemia and cardiovascular disease (CVD).
    Inclisiran
  • HY-132610
    Givosiran
    		98.51%
    Givosiran (ALN-AS1) is a small interfering RNA that targets hepatic aminolevulinate synthase 1 (ALAS1) messenger RNA. Givosiran downregulates ALAS1 mRNA and prevents accumulation of neurotoxic δ-aminolevulinic acid and porphobilinogen levels. Givosiran can be used for the research of acute intermittent porphyria.
    Givosiran
  • HY-RS29442
    Nsun2 Mouse Pre-designed siRNA Set A
    		Pre-designed Sets
    Nsun2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Nsun2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Components
    Nsun2 Mouse Pre-designed siRNA Set A-1
    Nsun2 Mouse Pre-designed siRNA Set A-2
    Nsun2 Mouse Pre-designed siRNA Set A-3
    siRNA Negative Control
    FAM-labeled siRNA Negative Control
    GAPDH Positive Control siRNA (Mouse)
    Nsun2 Mouse Pre-designed siRNA Set A
    Nsun2 Mouse Pre-designed siRNA Set A
  • HY-RS15942A
    YWHAG Human Pre-designed siRNA Set A-3
    YWHAG Human Pre-designed siRNA Set A-3 includes three pairs of siRNA designed for different regions of the YWHAG (Human) gene, along with a negative control, a FAM-labeled negative control, and a positive control.
    YWHAG Human Pre-designed siRNA Set A-3
    YWHAG Human Pre-designed siRNA Set A-3
  • HY-164970
    TANGO1-L Human scramble negative control
    TANGO1-L Human scramble negative control is the scrambled negative control for TANGO1-L small interfering RNA.
    TANGO1-L Human scramble negative control
  • HY-132610A
    Givosiran sodium
    		98.71%
    Givosiran sodium is a small interfering RNA that targets hepatic aminolevulinate synthase 1 (ALAS1) messenger RNA. Givosiran sodium downregulates ALAS1 mRNA and prevents accumulation of neurotoxic δ-aminolevulinic acid and porphobilinogen levels. Givosiran sodium can be used for the research of acute intermittent porphyria.
    Givosiran sodium
  • HY-119024
    BCI-137
    		99.55%
    BCI-137 is a competitive AGO2 inhibitor, with an IC50 of 342 μM. BCI-137 tightly binds to several residues of the Mid domain.
    BCI-137
  • HY-132588
    Lumasiran
    Lumasiran (ALN-G01), a siRNA product, reduces hepatic oxalate production by targeting glycolate oxidase. By silencing the gene encoding glycolate oxidase, Lumasiran depletes glycolate oxidase and thereby inhibits the synthesis of oxalate, which is the toxic metabolite that is directly associated with the clinical manifestations of Primary hyperoxaluria type 1 (PH1).
    Lumasiran
  • HY-147425A
    Zerlasiran sodium
    		Inhibitor
    Zerlasiran sodium is an apolipoprotein A (ApoA) synthesis reducer.
    Zerlasiran sodium
  • HY-132589A
    Vutrisiran sodium
    Vutrisiran sodium is a liver-directed, investigational, small interfering ribonucleic acid (siRNA) agent. Vutrisiran sodium can be used for transthyretin (TTR)-mediated amyloidosis research.
    Vutrisiran sodium
  • HY-145720
    Cemdisiran
    Cemdisiran is an N-acetylgalactosamine (GalNAc) conjugated siRNA for the research of complement-mediated diseases by suppressing liver production of complement 5 (C5) protein.
    Cemdisiran
  • HY-132613
    Lumasiran sodium
    		99.21%
    Lumasiran sodium, an investigational RNA interference (RNAi) therapeutic agent, reduces hepatic oxalate production by targeting glycolate oxidase. Lumasiran sodium reduces urinary oxalate excretion, the cause of progressive kidney failure in primary hyperoxaluria type 1 (PH1) .
    Lumasiran sodium
  • HY-150223
    GalNAc unconjugated/naked Inclisiran
    GalNAc unconjugated/naked Inclisiran is a double-stranded small interfering RNA (siRNA) without GalNAc conjugation. GalNAc unconjugated/naked Inclisiran inhibits the transcription of PCSK-9, and can be used for hyperlipidemia and cardiovascular disease (CVD) research.
    GalNAc unconjugated/naked Inclisiran
  • HY-RS13702
    SPP1 Human Pre-designed siRNA Set A
    		Pre-designed Sets

    SPP1 Human Pre-designed siRNA Set A contains three designed siRNAs for SPP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    SPP1 Human Pre-designed siRNA Set A
    SPP1 Human Pre-designed siRNA Set A
  • HY-132606A
    Nedosiran sodium
    Nedosiran (DCR-PHXC) sodium is an RNA interference (RNAi) targeting lactate dehydrogenase (LDH). Nedosiran sodium represents an impactful potential therapeutic for primary hyperoxaluria (PH) with end-stage renal disease (ESRD). Nedosiran sodium is a GalNAc-dsRNA conjugate.
    Nedosiran sodium
  • HY-132589
    Vutrisiran
    Vutrisiran (ALN-TTRsc02) is a liver-directed, investigational, small interfering ribonucleic acid (siRNA) agent. Vutrisiran can be used for transthyretin (TTR)-mediated amyloidosis research.
    Vutrisiran
  • HY-132587
    Fitusiran
    Fitusiran (ALN-AT3SC), an small interfering RNA, specifically targets antithrombin (AT) messenger RNA to lower production of AT in the liver. Fitusiran increases thrombin generation and has the potential for the research of the hemophilia.
    Fitusiran